Mohamed A Gouda/X
Jan 21, 2025, 09:42
Mohamed A. Gouda: Selpercatinib mitigates cancer cachexia independent of anti-tumor activity
Mohamed A. Gouda, Clinical Fellow at the University of Texas MD Anderson Cancer Center, shared a post on X about a recent paper by Ujjwol Khatri et al. published in Cancer Letters:
“Following observations we previously reported on weight gain as a side effect to selective RET inhibitors (PMID: 37473872), now new data on associations independent of anti-tumor activity!”
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model
Authors: Ujjwol Khatri et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 22:37
Sep 2, 2025, 22:03
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54